Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
IGC Stock Forecast 2026-2027
$0.30
Current Price
$29.93M
Market Cap
Buy 2
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to IGC Price Targets
+1,655.9%
To High Target of $5.25
+1,279.6%
To Median Target of $4.13
+903.3%
To Low Target of $3.00
IGC Price Momentum
+3.4%
1 Week Change
-3.2%
1 Month Change
-3.2%
1 Year Change
+7.1%
Year-to-Date Change
-40.2%
From 52W High of $0.50
+24.6%
From 52W Low of $0.24
📊 TOP ANALYST CALLS
Did IGC Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if IGC is one of their latest high-conviction picks.
Latest IGC Stock Price Targets & Analyst Predictions
Based on our analysis of 1 Wall Street analyst, IGC has a bullish consensus with a median price target of $4.13 (ranging from $3.00 to $5.25). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $0.30, the median forecast implies a 1,279.6% upside. This outlook is supported by 2 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
IGC Analyst Ratings
2
Buy
0
Hold
0
Sell
IGC Price Target Range
Low
$3.00
Average
$4.13
High
$5.25
Current: $0.30
Latest IGC Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for IGC.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 8, 2026 | Ascendiant Capital | Buy | Maintains | $N/A | |
| Feb 23, 2026 | Ascendiant Capital | Buy | Maintains | $N/A | |
| Dec 9, 2025 | Ascendiant Capital | Buy | Maintains | $N/A | |
| Aug 26, 2025 | Ascendiant Capital | Buy | Maintains | $N/A | |
| Mar 6, 2025 | Alliance Global Partners | Buy | Reiterates | $N/A | |
| Feb 24, 2025 | Ascendiant Capital | Buy | Maintains | $N/A | |
| Dec 5, 2024 | Ascendiant Capital | Buy | Maintains | $N/A | |
| Sep 3, 2024 | Ascendiant Capital | Buy | Maintains | $N/A | |
| Jul 29, 2024 | Ascendiant Capital | Buy | Maintains | $N/A | |
| Jul 17, 2024 | Alliance Global Partners | Buy | Initiates | $N/A | |
| Jun 21, 2024 | Ascendiant Capital | Buy | Reiterates | $N/A |
IGC Pharma Inc. (IGC) Competitors
The following stocks are similar to IGC based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
IGC Pharma Inc. (IGC) Financial Data
IGC Pharma Inc. has a market capitalization of $29.93M with a P/E ratio of -3.3x. The company generates $1.11M in trailing twelve-month revenue with a 48.7% profit margin.
Revenue growth is -3.9% quarter-over-quarter, while maintaining an operating margin of -775.4% and return on equity of -83.3%.
Valuation Metrics
Market Cap
$29.93M
Enterprise Value
$29.31M
P/E Ratio
-3.3x
PEG Ratio
-3.4x
Price/Sales
25.9x
Growth & Margins
Revenue Growth (YoY)
-3.9%
Gross Margin
+17.4%
Operating Margin
-775.4%
Net Margin
+48.7%
EPS Growth
-3.9%
Financial Health
Cash/Price Ratio
+0.7%
Current Ratio
1.3x
Debt/Equity
15.0x
ROE
-83.3%
ROA
-50.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
IGC Pharma Inc. (IGC) Business Model
About IGC Pharma Inc.
What They Do
Develops innovative therapies for chronic conditions.
Business Model
The company generates revenue through the development and commercialization of therapies that leverage cannabinoid science. By focusing on chronic pain, cancer, and other life-altering conditions, IGC Pharma aims to meet unmet medical needs and capture market opportunities within the pharmaceutical and biotechnology sectors.
Additional Information
IGC Pharma is engaged in significant research and development with a robust pipeline of products at various stages of clinical trials. Its unique approach integrates traditional pharmaceutical methods with advancements in cannabinoid science, positioning the company as a potential leader in evolving treatment options.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
70
CEO
Mr. Ram Mukunda
Country
United States
IPO Year
2006
Website
igcpharma.comIGC Pharma Inc. (IGC) Latest News & Analysis
Latest News
Quick Summary
IGC Pharma reports that 80% of participants have completed the Phase 2 CALMA trial for IGC-AD1, now including Mount Sinai as a site, moving closer to database lock and analysis.
Why It Matters
Completion of 80% of trial participation boosts confidence in IGC Pharma's Alzheimer's treatment, potentially leading to positive trial results and increased stock value.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
IGC Pharma reported progress in its CALMA Phase 2 trial and expanded its clinical site network in its Q1 2026 report. The company focuses on Alzheimer's therapeutics and AI tools.
Why It Matters
Progress in IGC's CALMA Phase 2 trial indicates potential advancements in Alzheimer's treatment, which could lead to significant market opportunities and impact stock performance.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
IGC Pharma will present new Tau-PET biomarker research at the 2026 Global Tau Conference, focusing on Alzheimer's disease monitoring and therapeutic development.
Why It Matters
Advancements in Alzheimer's imaging analytics and IGC's research could enhance drug development, potentially increasing the company's value and attracting investor interest in the biotech sector.
Source: Accesswire
Market Sentiment:
Neutral
IGC Pharma Advances Caregiver Engagement as Phase 2 CALMA Trial Advances Final Enrollment Phase
1 month ago
Quick Summary
IGC Pharma is nearing 80% enrollment in its Phase 2 CALMA clinical trial for Alzheimer's therapeutics. The company is promoting awareness of agitation in Alzheimer's through a caregiver-focused podcast.
Why It Matters
IGC Pharma's outreach and nearing completion of patient enrollment in its Alzheimer's trial may boost confidence in its clinical progress, impacting stock performance and investor interest.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
IGC Pharma, Inc. (NYSE American: IGC) is nearing 80% enrollment in its Phase 2 CALMA trial for IGC-AD1 targeting Alzheimer's agitation, with Kerwin Medical Center added as a clinical site.
Why It Matters
IGC Pharma's progress in its Alzheimer's agitation study could indicate potential breakthroughs in treatment, impacting stock value and investor sentiment surrounding the biotech sector.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
IGC Pharma received authorization in Colombia to develop psilocybin therapeutics, enhancing its capabilities as it nears completion of its Phase 2 CALMA trial for Alzheimer's disease.
Why It Matters
IGC Pharma's authorization to work with psilocybin enhances its research portfolio in Alzheimer's, attracting investor interest amid growing trends in psychedelic therapeutics.
Source: Accesswire
Market Sentiment:
Neutral
Frequently Asked Questions About IGC Stock
What is IGC Pharma Inc.'s (IGC) stock forecast for 2026?
Based on our analysis of 1 Wall Street analysts, IGC Pharma Inc. (IGC) has a median price target of $4.13. The highest price target is $5.25 and the lowest is $3.00.
Is IGC stock a good investment in 2026?
According to current analyst ratings, IGC has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.30. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for IGC stock?
Wall Street analysts predict IGC stock could reach $4.13 in the next 12 months. This represents a 1,279.6% increase from the current price of $0.30. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is IGC Pharma Inc.'s business model?
The company generates revenue through the development and commercialization of therapies that leverage cannabinoid science. By focusing on chronic pain, cancer, and other life-altering conditions, IGC Pharma aims to meet unmet medical needs and capture market opportunities within the pharmaceutical and biotechnology sectors.
What is the highest forecasted price for IGC IGC Pharma Inc.?
The highest price target for IGC is $5.25 from at , which represents a 1,655.9% increase from the current price of $0.30.
What is the lowest forecasted price for IGC IGC Pharma Inc.?
The lowest price target for IGC is $3.00 from at , which represents a 903.3% increase from the current price of $0.30.
What is the overall IGC consensus from analysts for IGC Pharma Inc.?
The overall analyst consensus for IGC is bullish. Out of 1 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $4.13.
How accurate are IGC stock price projections?
Stock price projections, including those for IGC Pharma Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 9, 2026 3:01 AM UTC